ERA

Download the full-sized PDF of The potential of novel small inhibitory molecules to prevent the rejection of neonatal porcine islets in miceDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3BM7T

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

The potential of novel small inhibitory molecules to prevent the rejection of neonatal porcine islets in mice Open Access

Descriptions

Other title
Subject/Keyword
xenotransplantation, neonatal porcine islets, DR80, suramin, small inhibitory molecules
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Mihalicz, Dana
Supervisor and department
Rayat, Gina (Surgery)
Examining committee member and department
Baldwin, Troy (Medical Microbiology and Immunology)
Rajotte, Ray (Surgery)
Williams, David (Surgery)
Department
Surgery
Specialization

Date accepted
2011-08-11
Graduation date
2011-11
Degree
Master of Science
Degree level
Master's
Abstract
The objectives of this study were to determine the effect of small inhibitory molecules suramin and DR80 on T cell proliferation in vitro as well as in vivo by preventing the rejection of neonatal porcine islets (NPI) in mice when combined with anti-LFA-1 monoclonal antibody (mAb). Suramin and DR80 inhibited T cell proliferation in vitro in a dose dependent manner with minimal cytotoxicity. As a monotherapy, neither suramin, DR80, nor anti-LFA-1 mAb prevented the rejection of NPI transplants. One of seven mouse recipients treated with suramin and anti-LFA-1 mAb and 6/10 mouse recipients treated with DR80 and anti-LFA-1 mAb achieved normoglycemia for more than 100 days after transplantation; 1 of the mice in the latter group subsequently rejected the NPI transplant. In conclusion, our findings indicates that the combination of DR80 and anti-LFA-1 mAb may be a promising therapy to prevent rejection of NPI in individuals with type 1 diabetes.
Language
English
DOI
doi:10.7939/R3BM7T
Rights
License granted by Dana Mihalicz (mihalicz@ualberta.ca) on 2011-08-05T03:15:06Z (GMT): Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of the above terms. The author reserves all other publication and other rights in association with the copyright in the thesis, and except as herein provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-04-30T22:09:29.178+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 77798038
Last modified: 2015:10:12 16:28:31-06:00
Filename: Mihalicz_Dana_Fall_2011.pdf
Original checksum: fbf1608566be86f78b821dc0d9194b2d
Well formed: true
Valid: true
Status message: File header gives version as 1.4, but catalog dictionary gives version as 1.3
File title: Microsoft Word - Mihalicz_Dana_Spring2011.doc
File author: Dana Mihalicz
Page count: 119
Activity of users you follow
User Activity Date